{"doi":"10.1056/nejmoa2403407","title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma","abstract":null,"journal":"New England Journal of Medicine","year":2024,"id":627397,"datarank":0.7676990718625134,"base_score":5.117993812416755,"endowment":5.117993812416755,"self_citation_contribution":0.7676990718625134,"citation_network_contribution":0.0,"self_endowment_contribution":0.7676990718625134,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":166,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1623830,"name":"Meral Beksac","orcid":null,"position":1,"is_corresponding":false},{"id":1623831,"name":"Ludek Pour","orcid":null,"position":2,"is_corresponding":false},{"id":1623832,"name":"Sosana Delimpasi","orcid":null,"position":3,"is_corresponding":false},{"id":1522697,"name":"Vladimir Vorobyev","orcid":null,"position":4,"is_corresponding":false},{"id":1338785,"name":"Hang Quach","orcid":"0000-0002-4796-3352","position":5,"is_corresponding":false},{"id":1623833,"name":"Ivan Spicka","orcid":null,"position":6,"is_corresponding":false},{"id":1022473,"name":"Jakub Radocha","orcid":"0000-0002-5384-8238","position":7,"is_corresponding":false},{"id":1623836,"name":"Pawel Robak","orcid":null,"position":8,"is_corresponding":false},{"id":1583049,"name":"Kihyun Kim","orcid":null,"position":9,"is_corresponding":false},{"id":1529158,"name":"Michele Cavo","orcid":null,"position":10,"is_corresponding":false},{"id":1623838,"name":"Kazuhito Suzuki","orcid":null,"position":11,"is_corresponding":false},{"id":523138,"name":"Kristin Morris","orcid":null,"position":12,"is_corresponding":false},{"id":1623839,"name":"Farrah Pompilus","orcid":null,"position":13,"is_corresponding":false},{"id":1623840,"name":"Amy Phillips-Jones","orcid":null,"position":14,"is_corresponding":false},{"id":1623841,"name":"Xiaoou L. Zhou","orcid":null,"position":15,"is_corresponding":false},{"id":939026,"name":"Giulia Fulci","orcid":"0000-0002-2059-9562","position":16,"is_corresponding":false},{"id":1623842,"name":"Neal Sule","orcid":null,"position":17,"is_corresponding":false},{"id":159814,"name":"Brandon E. Kremer","orcid":null,"position":18,"is_corresponding":false},{"id":635511,"name":"Joanna Opalinska","orcid":null,"position":19,"is_corresponding":false},{"id":1623843,"name":"María-Victoria Mateos","orcid":null,"position":20,"is_corresponding":false},{"id":25438,"name":"Suzanne Trudel","orcid":"0000-0001-7952-6352","position":21,"is_corresponding":false},{"id":1623829,"name":"Meletios Athanasios Dimopoulos","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma","abstract":"BACKGROUND: Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse. Frontline lenalidomide therapy has increased the number of patients with lenalidomide-refractory disease at the time of the first relapse. METHODS: In this phase 3, randomized, open-label trial, we evaluated belantamab mafodotin, pomalidomide, and dexamethasone (BPd), as compared with pomalidomide, bortezomib, and dexamethasone (PVd), in lenalidomide-exposed patients who had relapsed or refractory myeloma after at least one line of therapy. The primary end point was progression-free survival. Disease response and safety were also assessed. RESULTS: A total of 302 patients underwent randomization; 155 were assigned to the BPd group, and 147 to the PVd group. At a median follow-up of 21.8 months (range, <0.1 to 39.2), the 12-month estimated progression-free survival with BPd was 71% (95% confidence interval [CI], 63 to 78), as compared with 51% (95% CI, 42 to 60) with PVd (hazard ratio for disease progression or death, 0.52; 95% CI, 0.37 to 0.73; P<0.001). Data on overall survival were immature. The percentage of patients with a response to treatment (partial response or better) was 77% (95% CI, 70 to 84) in the BPd group and 72% (95% CI, 64 to 79) in the PVd group; 40% (95% CI, 32 to 48) and 16% (95% CI, 11 to 23), respectively, had a complete response or better. Grade 3 or higher adverse events occurred in 94% of the patients in the BPd group and 76% of those in the PVd group. Ocular events occurred in 89% of the patients who received BPd (grade 3 or 4 in 43%) and 30% of those who received PVd (grade 3 or 4 in 2%); ocular events in the BPd group were managed with belantamab mafodotin dose modification. Ocular events led to treatment discontinuation in 9% of the patients in the BPd group and in no patients in the PVd group. CONCLUSIONS: Among lenalidomide-exposed patients with relapsed or refractory myeloma, BPd conferred a significantly greater benefit than PVd with respect to progression-free survival, as well as deeper, more durable responses. Ocular events were common but were controllable by belantamab mafodotin dose modification. (Funded by GSK; DREAMM-8 ClinicalTrials.gov number, NCT04484623; EudraCT number, 2018-004354-21.).","is_dataset_classified":null,"base_score":5.10594547390058,"endowment":5.10594547390058,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38828951","pmcid":null,"openalex_id":"https://openalex.org/W4399275686","authors":[],"funders":[{"funder_name":"GlaxoSmithKline","grant_id":"","title":null}],"total_grants":1,"fwci":48.839,"citation_percentile":0.99943394,"influential_citations":0,"citation_trend":[{"year":2024,"count":24},{"year":2025,"count":87},{"year":2026,"count":53}],"oa_status":"closed","license":"http://www.nejmgroup.org/legal/terms-of-use.htm","oa_locations":[{"url":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa2403407","host_type":"publisher"},{"url":"https://doi.org/10.1056/nejmoa2403407","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38828951","host_type":"repository"},{"url":"https://www.nejm.org/doi/10.1056/NEJMoa2403407","host_type":"repository"}],"fields_of_study":["Multiple Myeloma Research and Treatments","Ubiquitin and proteasome pathways","Acute Myeloid Leukemia Research"],"mesh_terms":["Bortezomib","Lenalidomide","Progression-Free Survival","Adult","Aged","Aged, 80 and over","Antineoplastic Combined Chemotherapy Protocols","Dexamethasone","Eye Diseases","Female","Humans","Male","Middle Aged","Multiple Myeloma","Neoplasm Recurrence, Local","Recurrence","Thalidomide","Treatment Outcome","Disease Progression","Drug Resistance, Neoplasm","Kaplan-Meier Estimate","Antibodies, Monoclonal, Humanized"],"keywords":["Pomalidomide","Lenalidomide","Medicine","Internal medicine","Hazard ratio","Dexamethasone","Multiple myeloma","Thalidomide","Clinical endpoint","Gastroenterology","Confidence interval","Randomized controlled trial","Oncology","Surgery"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"eudract"},{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T17:23:53.461825Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}